TOOLS FOR PRACTICE #356 | January 08, 2024



(A)dressing the Christmas Tree? Therapies for pityriasis rosea.

CLINICAL QUESTION

What therapies improve resolution of pityriasis rosea (Christmas tree rash)?

BOTTOM LINE

Pityriasis rosea is self-limiting. Based on limited evidence, oral corticosteroids reduce itch and rash for ~95% of patients while acyclovir is effective in ~70% of patients versus 30-60% on placebo at 1-2 weeks. Macrolides likely ineffective. Little/no evidence for topical corticosteroids or oral antihistamines.

EVIDENCE

- One systematic review¹ studying all treatments and 1 acyclovir² (age 2-60). Outcomes at 2-weeks; statistically significant unless stated.
- Prednisolone (20mg tapered over 15-days) versus placebo [1 randomized, controlled trial (RCT), 70 patients]:¹
 - Resolved itch: 94% versus 32% (placebo).
 - Good/excellent rash improvement: 97% versus 60% (placebo).
- Acyclovir 400-800mg 5x daily 7-days:^{1,2}
 - Versus placebo/vitamins/no treatment (3 RCTs 141 patients):1
 - Good/excellent rash reduction: 67% versus 28% (control).¹
 - Versus no acyclovir with calamine lotion and cetirizine 10mg (both arms) (1 RCT, 24 patients):¹

- Itch resolution: 75% versus 17% (no acyclovir).
- Lesion score³ (1-5, higher worse, baseline=4.1): 0.9 versus 3 (no acyclovir).
- Macrolides:
 - Clarithromycin or azithromycin versus placebo (4 RCTs, 207 patients):1
 - Rash/itch improvement: No difference.
 - Erythromycin 1gram daily x7-14 days versus placebo:1
 - Itch score reduction (1-10, more reduction=better) (1 RCT, 34 patients): 5.7 versus
 1.8 (placebo).
 - Rash improvement (2 RCTs, 86 patients): No difference.
 - Gastrointestinal upset: 12% versus 6% (placebo).
- Topical corticosteroids: No RCTs.¹
- Antihistamines:¹ Dexchlorpheniramine versus oral betamethasone versus combined (1 RCT, 85 patients).¹
 - Dexchlorpheniramine versus Betamethasone: No difference.
 - Either versus combined: No difference in itch, but rash improved more in either alone versus combined (likely spurious).
- Limitations: Few/small studies, some unblinded.¹

CONTEXT

- Distribution of secondary lesions along Langer lines, appearing ≤6 weeks after herald patch. Selflimiting lasting ~45 days with moderate-severe pruritis in 30-50%.¹
- Guidance:⁴
 - Consider antihistamines or topical/oral corticosteroids if symptoms severe.
 - Consider acyclovir in pregnancy but pityriasis rosea risks inconsistent/unclear. Example, case-series (38 pregnancies) suggesting first-trimester had higher pregnancy loss⁵ not supported in subsequent case-series (53 and 33 pregnancies).^{6,7} Treatment effect unknown.
- Proposed viral etiology (examples HHV-6, HHV-7), with constitutional symptoms ~69%.⁴
- Not to be confused with tinea (pityriasis) versicolor, caused by Malassezia yeast genus.⁸

REFERENCES

- 1. Contreras-Ruiz J, Peternel S, Jiménez-Gutiérrez C, *et al.* Cochrane Database Syst Rev. 2019; 10:CD005068.
- 2. Rodriguez-Zuniga M, Torres N, Garcia-Perdomo H. An Bras Dermatol. 2018; 93(5):686-95.
- 3. Das A, Sil A, Das NK, *et al.* Indian Dermatol Online J. 2015; 6(3):181-4.
- 4. Villalon-Gomez J. Am Fam Physician. 2018; 97(1):38-44.
- 5. Drago F, Broccolo F, Zaccaria E, *et al.* J Am Acad Dermatol. 2008; 58(5 suppl 1): S78-S83.
- 6. Wenger-Oehn L, Graier T, Ambros-Rudolph C, *et al.* J Dtsch Dermatol Ges. 2022; 20(7):953-959.
- 7. Stashower J, Bruch K, Mosby A *et al.* J Am Acad Derm. 2021; 85(6):1648-9.
- 8. Leung AK, Barankin B, Lam JM, *et al.* Drugs Context. 2022; 11:2022-9-2.

AUTHORS

Jennifer Young, MD, CCFP-EM Émélie Braschi, MD PhD G Michael Allan, MD CCFP

Authors do not have any conflicts of interest to declare.





IN PARTNERSHIP WITH



Tools for Practice are peer reviewed and summarize practice-changing medical evidence for primary care. Coordinated by **Dr. G. Michael Allan** and **Dr. Adrienne Lindblad**, they are developed by the Patients, Experience, Evidence, Research (PEER) team, and supported by the College of Family Physicians of Canada, and the Alberta, Ontario, and Saskatchewan Colleges of Family Physicians. Feedback is welcome and can be sent to toolsforpractice@cfpc.ca. Archived articles can be found at www.toolsforpractice.ca

This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the College of Family Physicians of Canada.